UBS Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

UBS Group’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-28,800	Closed	-$1.18M	–	10436
2024 Q2	$1.18M	Sell	28,800 -27,600	-49%	-$1.15M	﹤0.01%	4259
2024 Q1	$2.38M	Sell	56,400 -45,600	-45%	-$1.92M	﹤0.01%	3767
2023 Q4	$4.32M	Buy	102,000 +46,400	+83%	+$1.33M	﹤0.01%	2934
2023 Q3	$1.21M	Hold	55,600	–	–	﹤0.01%	3908
2023 Q2	$1.77M	Hold	55,600	–	–	﹤0.01%	3650
2023 Q1	$1.36M	Buy	+55,600	New	+$1.63M	﹤0.01%	3824

Other funds holding CERE

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

UBS Group's CERE Position: Q3 2024 in Review

UBS Group sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 291,457 shares — an estimated $11.9M sold.

UBS Group first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $12.9M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

UBS Group reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
UBS Group sold 291,457 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $11.9M.
UBS Group first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
UBS Group's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $12.9M in Q1 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on UBS Group's 13F filing for Q3 2024, filed 14 Nov 2024.